Related Experiment Video
Updated: Dec 10, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Technology Considerations for Enabling eSource in Clinical Research: Industry Perspective
Donald G Jennings1, Amy Nordo2, Aruna Vattikola3
1Digital Health, Eli Lilly and Company, MC/525/02, Indianapolis, IN, 46285, USA. donald.jennings@lilly.com.
Background:
The technological complexities and broad operational scope of eSource impede coordinated, inter-organizational action on advancing at-scale solutions.
Methods:
We introduce an architectural framework for articulating technological considerations across organizations. The architecture neither implies nor endorses solution implementations; rather, it proposes solution functionality based upon principles and good clinical practices.
Results:
Key technology considerations include patterns of anticipated use, implications to the current state of clinical trial operations, and the need for new technologies (i.e., IoT, Big Data, Predictive Analytics).
Conclusion:
Technology considerations drive implications beyond technology-influencing regulatory, process, and ethical realms of clinical research.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

